LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis

Ítems similars

• 1502 Lupus low disease activity state attainment in the phase 3 placebo-controlled TULIP long-term extension trial of anifrolumab
  per: Richard A Furie, et al.
  Publicat: (2024-05-01)
• Targeting DORIS Remission and LLDAS in SLE: A Review
  per: Agner R. Parra Sánchez, et al.
  Publicat: (2023-10-01)
• Correction: Targeting DORIS Remission and LLDAS in SLE: A Review
  per: Agner R. Parra Sánchez, et al.
  Publicat: (2024-06-01)
• 22 New and approved therapies for SLE: Anifrolumab
  per: Ronald van Vollenhoven
  Publicat: (2022-04-01)
• 06 Approved biologics for SLE: which to try first and in which patients? – The case for anifrolumab
  per: Eric Morand
  Publicat: (2023-09-01)